{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:04:07Z","timestamp":1784034247444,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>MALT1 forms part of a central signaling node downstream of immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, across a broad range of immune cell subsets, and regulates NF-\u03baB driven transcriptional responses <jats:italic>via<\/jats:italic> dual scaffolding-protease activity. Allosteric inhibition of MALT1 activity has demonstrated benefit in animal models of inflammation. However, development of MALT1 inhibitors to treat autoimmune and inflammatory diseases (A&amp;amp;ID) has been hindered by reports linking MALT1 inhibition and genetic loss-of-function to reductions in regulatory T-cell (Treg) numbers and development of auto-inflammatory syndromes. Using an allosteric MALT1 inhibitor, we investigated the consequence of pharmacological inhibition of MALT1 on proinflammatory cells compared to regulatory T-cells. Consistent with its known role in ITAM-driven responses, MALT1 inhibition suppressed proinflammatory cytokine production from activated human T-cells and monocyte-derived macrophages, and attenuated B-cell proliferation. Oral administration of a MALT1 inhibitor reduced disease severity and synovial cytokine production in a rat collagen-induced arthritis model. Interestingly, reduction in splenic Treg numbers was less pronounced in the context of inflammation compared with na\u00efve animals. Additionally, in the context of the disease model, we observed an uncoupling of anti-inflammatory effects of MALT1 inhibition from Treg reduction, with lower systemic concentrations of inhibitor needed to reduce disease severity compared to that required to reduce Treg numbers. MALT1 inhibition did not affect suppressive function of human Tregs <jats:italic>in vitro<\/jats:italic>. These data indicate that anti-inflammatory efficacy can be achieved with MALT1 inhibition without impacting the number or function of Tregs, further supporting the potential of MALT1 inhibition in the treatment of autoimmune disease.<\/jats:p>","DOI":"10.3389\/fimmu.2022.875320","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T09:53:00Z","timestamp":1652089980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled From Effects on Regulatory T-Cells"],"prefix":"10.3389","volume":"13","author":[{"given":"Subhabrata","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Chalishazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ynes","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"DiSpirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"DeChristopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy","family":"Merselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102531","article-title":"Worldwide Trends in All-Cause Mortality of Auto-Immune Systemic Diseases Between 2001 and 2014","volume":"19","author":"Scherlinger","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01927","article-title":"Holding All the CARDs: How MALT1 Controls CARMA\/CARD-Dependent Signaling","volume":"9","author":"Juilland","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0087-2","article-title":"CARD\u2013BCL-10\u2013MALT1 Signalling in Protective and Pathological Immunity","volume":"19","author":"Ruland","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201351","article-title":"Paracaspase MALT1 Deficiency Protects Mice From Autoimmune-Mediated Demyelination","volume":"190","author":"Mc Guire","year":"2013","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1742-2094-11-124","article-title":"Pharmacological Inhibition of MALT1 Protease Activity Protects Mice in a Mouse Model of Multiple Sclerosis","volume":"11","author":"Mc Guire","year":"2014","journal-title":"J Neuroinflamm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11889","DOI":"10.1038\/s41598-017-12349-9","article-title":"Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 as a Novel Therapeutic Target for Rheumatoid Arthritis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e49237","DOI":"10.15252\/embr.201949237","article-title":"MALT 1 Targeting Suppresses CARD 14-Induced Psoriatic Dermatitis in Mice","volume":"21","author":"Van Nuffel","year":"2020","journal-title":"EMBO Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001031","article-title":"Intrinsic Abnormalities of Keratinocytes Initiate Skin Inflammation Through the IL-23\/T17 Axis in a MALT1-Dependent Manner","volume":"206","author":"Zhang","year":"2021","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-018-1207-y","article-title":"Malt1 Inactivation Attenuates Experimental Colitis Through the Regulation of Th17 and Th1\/17 Cells","volume":"68","author":"Nakamura","year":"2019","journal-title":"Inflamm Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8867","article-title":"MALT1 Inhibitors Prevent the Development of DSS-Induced Experimental Colitis in Mice via Inhibiting NF-\u03bab and NLRP3 Inflammasome Activation","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.12.004","article-title":"Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad","volume":"22","author":"Demeyer","year":"2016","journal-title":"Trends Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801614","article-title":"Malt1 Protease Is Critical in Maintaining Function of Regulatory T Cells and May Be a Therapeutic Target for Antitumor Immunity","volume":"202","author":"Cheng","year":"2019","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00745","article-title":"Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology","volume":"11","author":"Martin","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101557","article-title":"Long-Term MALT1 Inhibition in Adult Mice Without Severe Systemic Autoimmunity","volume":"23","author":"Demeyer","year":"2020","journal-title":"iScience"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222548","article-title":"A MALT1 Inhibitor Suppresses Human Myeloid DC, Effector T-Cell and B-Cell Responses and Retains Th1\/regulatory T-Cell Homeostasis","volume":"15","author":"Dumont","year":"2020","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph10093834","article-title":"Optimal Method to Stimulate Cytokine Production and Its Use in Immunotoxicity Assessment","volume":"10","author":"Ai","year":"2013","journal-title":"IJERPH"},{"key":"B18","doi-asserted-by":"publisher","first-page":"315ra819","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 Diabetes Immunotherapy Using Polyclonal Regulatory T Cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402254","article-title":"Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation","volume":"194","author":"Bornancin","year":"2015","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.27503","article-title":"Evaluation of Therapeutic Targets in Animal Models of Arthritis: How Does it Relate to Rheumatoid Arthritis","volume":"62","author":"Bevaart","year":"2010","journal-title":"Arthritis Rheumatism"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156","article-title":"The Role of Interleukin-2 During Homeostasis and Activation of the Immune System","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1038\/s41467-019-10203-2","article-title":"Bcl10-Controlled Malt1 Paracaspase Activity is Key for the Immune Suppressive Function of Regulatory T Cells","volume":"10","author":"Rosenbaum","year":"2019","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.10.5814","article-title":"IL-17 Stimulates Intraperitoneal Neutrophil Infiltration Through the Release of Gro\u03b1 Chemokine From Mesothelial Cells","volume":"165","author":"Witowski","year":"2000","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/imcb.1018","article-title":"The T-Cell Fingerprint of MALT1 Paracaspase Revealed by Selective Inhibition","volume":"96","author":"Bardet","year":"2018","journal-title":"Immunol Cell Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.875320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T09:53:04Z","timestamp":1652089984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.875320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2022.875320"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.875320","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"875320"}}